PALIPERIDONE PALMITATE | N207946 | JANSSEN PHARMACEUTICALS INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
JANSSEN PHARMACEUTICALS, INC. et al v. MYLAN LABORATORIES LIMITED et al 1 patentANDA 216228paliperidone palmitate extended-release injectable suspension | D.N.J. | 2021-10-14 | Terminated 2022-01-07 | — |
JANSSEN PHARMACEUTICALS, INC. et al v. MYLAN LABORATORIES LIMITED 1 patentANDA 215682paliperidone palmitate extended-release injectable suspension | D.N.J. | 2021-08-11 | Terminated 2022-01-07 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$4233.40
per ml
Lowest NADAC/Unit
$3973.38
per ml
Brand NDCs
6
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 50458061201INVEGA HAFYERA 1,560 MG/5 ML | $4233.40 | ML | Brand | — | 2026-01-02 |
| 50458061101INVEGA HAFYERA 1,092 MG/3.5 ML | $4018.06 | ML | Brand | — | 2026-01-02 |
| 50458060801INVEGA TRINZA 546 MG/1.75 ML | $4011.11 | ML | Brand | — | 2026-06-17 |
| 50458060901INVEGA TRINZA 819 MG/2.63 ML | $4001.53 | ML | Brand | — | 2026-06-17 |
| 50458060601INVEGA TRINZA 273 MG/0.88 ML | $3988.84 | ML | Brand | — | 2026-01-02 |
| 50458060701INVEGA TRINZA 410 MG/1.32 ML | $3973.38 | ML | Brand | — | 2026-01-02 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 10143693 | Apr 5, 2036 | — | — | — | — |